KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Interest Income

Income earned on cash, deposits, and investments held by the company.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Interest Income · Q4 FY2026 · quarter ended Dec 2025

Interest income of $2.55M in Q4 FY2026

Q4 FY2026 interest income was $2.55M. Trailing-twelve-month interest income was $9.64M.

Context

  • Interest income amounted to 11.8% of revenue in FY2026.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near $2.55M or moves back toward the trailing-twelve-month quarterly average of $2.41M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$2.55M+35.9% QoQ
Last fiscal yearDec 2025
$8.68M— YoY
LTMDec 2025
$9.64M— YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2026
8.68M USD
Year-over-year change
+34.9%
4-year CAGR
+68.0%

Interest Income vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 interest income of $9.64M is the 6th highest of the 10 companies compared; the peer median is $12.21M.
  • Interest income amounts to 8.3% of revenue for KALV, versus a peer median of 16.1%.
KALV Competitors Peer median
Interest Income for KALV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCYCBicycle Therapeutics plcLTM Mar 2026$24.93M -32.8%+70.4%39.3%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$18.76M -30.2%+96.3%21.3%
OMEROmeros CorporationLTM Mar 2026$16.69M +85.2%+7.6%168.7%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$16.48M +18.9%+93.8%—
PRTAProthena Corporation plcLTM Mar 2026$12.21M -46.9%+30.6%21.1%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$9.64M ——8.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$8.75M -23.1%+50.8%11.1%
VSTMVerastem, Inc.LTM Mar 2026$4.4M +17.7%+49.6%8.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$4.3M +105.5%+75.2%1.4%
GOSSGossamer Bio, Inc.LTM Mar 2026$2.03M +17.4%+7.6%3.7%
Peer median (excluding KALV) $12.21M+17.4%+50.8%16.1%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Revenue000073.62M
Cost of Revenue0086.17M06.08M
Gross Profit00(86.17M)067.54M
Gross Margin————91.7%
Research & Development70.17M80.28M86.17M71.71M55.64M
Selling, General & Admin26.45M30.6M54.28M116.29M183.74M
Operating Expenses96.61M110.87M54.28M188M239.38M
Depreciation & Amortization564K718K816K941K1.45M
EBITDA(80.75M)(94.37M)(134.28M)(173.33M)(150.62M)
EBITDA Margin————-204.6%
Operating Income(96.61M)(110.87M)(140.45M)(188M)(171.84M)
Operating Margin————-233.4%
Interest Income1.09M2.23M3.9M6.44M8.68M
Interest Expense0005.79M19.34M
Other Income / Expenses14.27M17.96M5.35M7.94M420K
Income Before Tax(82.34M)(92.91M)(135.1M)(180.05M)(171.42M)
Pre-Tax Margin————-232.9%
Income Tax Expense00(8.45M)3.39M(7.13M)
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Net Margin————-223.2%
EPS (Basic)(3.36)(3.33)(3.44)(3.69)(3.23)
EPS (Diluted)(3.36)(3.33)(3.44)(3.69)(3.23)
Weighted Avg Shares24.47M27.89M36.79M49.65M50.9M
Weighted Avg Shares (Diluted)24.47M27.89M36.79M49.65M50.9M

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.